Submit Manuscript  

Article Details


Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways

[ Vol. 18 , Issue. 12 ]

Author(s):

Elisa Molinelli*, Anna Campanati, Valerio Brisigotti and Annamaria Offidani   Pages 964 - 978 ( 15 )

Abstract:


Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.

Methods: Biologics licensed for psoriasis include the TNF╬▒ inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).

Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.

Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.

Keywords:

Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.

Affiliation:

Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona



Read Full-Text article